TNF inhibition and sepsis -- sounding a cautionary note.
Grau
G E
GE
Maennel
D N
DN
D000818:Animals; D015703:Antigens, CD / Q000008:administration & dosage / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D006801:Humans; D007143:Immunoglobulin Heavy Chains / Q000008:administration & dosage / Q000627:therapeutic use; D007142:Immunoglobulin gamma-Chains; D051379:Mice; D018345:Mice, Knockout; D010215:Papio; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage / Q000627:therapeutic use; D047889:Receptors, Tumor Necrosis Factor, Type II; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D018805:Sepsis / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D015703:Antigens, CD; D007143:Immunoglobulin Heavy Chains; D007142:Immunoglobulin gamma-Chains; D018124:Receptors, Tumor Necrosis Factor; D047889:Receptors, Tumor Necrosis Factor, Type II; D011993:Recombinant Fusion Proteins; D014409:Tumor Necrosis Factor-alpha; C099374:Ro 45-2081